Many bacterial infections can be treated with the use of antibiotics. These medications continue to reduce morbidity and mortality; unfortunately, their use has brought about drug-resistant pathogens that produce difficult-to-treat infections, which require more extreme treatments. New antibiotics are needed to combat this ever-evolving resistance pathogenesis.
TessierJSifriCD. Epidemiology and prevention of bacterial infections in patients with hematologic malignancies. Infect Disord Drug Targets. 2011;11(1):11-17. doi:10.2174/187152611794407728.
2.
Centers for Disease Control and Prevention, Office of Infectious Diseases. Antibiotic resistance threats in the United States, 2013. http://www.cdc.gov/drugresistance/threat-report-2013. Published April2013. Accessed August 23, 2017.
LeekhaSTerrellCLEdsonRS. General principles of antimicrobial therapy. Mayo Clin Proc. 2011;86(2):156-167. doi:10.4065/mcp.2010.0639.
5.
GiamarellouH.Treatment options for multidrug-resistant bacteria. Expert Rev Anti Infect Ther. 2006;4(4):601-618.
6.
DilworthTJSliwinskiJRyanKDoddMMercierRC. Evaluation of vancomycin in combination with piperacillin-tazobactam or oxacillin against clinical methicillin-resistant Staphylococcus aureus isolates and vancomycin-intermediate S. aureus isolates in vitro. Antimicrob Agents Chemother. 2014;58:1028-1033. doi:10.1128/aac.01888-13.
